Back to Search Start Over

Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.

Authors :
de Billy E
Pellegrino M
Orlando D
Pericoli G
Ferretti R
Businaro P
Ajmone-Cat MA
Rossi S
Petrilli LL
Maestro N
Diomedi-Camassei F
Pezzullo M
De Stefanis C
Bencivenga P
Palma A
Rota R
Del Bufalo F
Massimi L
Weber G
Jones C
Carai A
Caruso S
De Angelis B
Caruana I
Quintarelli C
Mastronuzzi A
Locatelli F
Vinci M
Source :
Neuro-oncology [Neuro Oncol] 2022 Jul 01; Vol. 24 (7), pp. 1150-1163.
Publication Year :
2022

Abstract

Background: Diffuse midline gliomas (DMG) H3K27M-mutant, including diffuse intrinsic pontine glioma (DIPG), are pediatric brain tumors associated with grim prognosis. Although GD2-CAR T-cells demonstrated significant anti-tumor activity against DMG H3K27M-mutant in vivo, a multimodal approach may be needed to more effectively treat patients. We investigated GD2 expression in DMG/DIPG and other pediatric high-grade gliomas (pHGG) and sought to identify chemical compounds that would enhance GD2-CAR T-cell anti-tumor efficacy.<br />Methods: Immunohistochemistry in tumor tissue samples and immunofluorescence in primary patient-derived cell lines were performed to study GD2 expression. We developed a high-throughput cell-based assay to screen 42 kinase inhibitors in combination with GD2-CAR T-cells. Cell viability, western blots, flow-cytometry, real time PCR experiments, DIPG 3D culture models, and orthotopic xenograft model were applied to investigate the effect of selected compounds on DIPG cell death and CAR T-cell function.<br />Results: GD2 was heterogeneously, but widely, expressed in the tissue tested, while its expression was homogeneous and restricted to DMG/DIPG H3K27M-mutant cell lines. We identified dual IGF1R/IR antagonists, BMS-754807 and linsitinib, able to inhibit tumor cell viability at concentrations that do not affect CAR T-cells. Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile. The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo, and in vivo.<br />Conclusion: Our study supports the development of IGF1R/IR inhibitors to be used in combination with GD2-CAR T-cells for treating patients affected by DMG/DIPG and, potentially, by pHGG.<br /> (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.)

Details

Language :
English
ISSN :
1523-5866
Volume :
24
Issue :
7
Database :
MEDLINE
Journal :
Neuro-oncology
Publication Type :
Academic Journal
Accession number :
34964902
Full Text :
https://doi.org/10.1093/neuonc/noab300